Search company, investor...

Kenta Biotech

kentabiotech.com

About Kenta Biotech

Kenta Biotech is focusing on the discovery and development of fully human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases.

Headquarters Location

Rehhagstrasse 79

CH - 3018,

Switzerland

Missing: Kenta Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kenta Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Kenta Biotech Patents

Kenta Biotech has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/13/2006

6/12/2012

Monoclonal antibodies, HLA-B alleles, Clusters of differentiation, Immunology, Immune system

Grant

Application Date

2/13/2006

Grant Date

6/12/2012

Title

Related Topics

Monoclonal antibodies, HLA-B alleles, Clusters of differentiation, Immunology, Immune system

Status

Grant

Latest Kenta Biotech News

Aridis Pharma Picks Up Kenta Biotech's Anti-Infection Products

May 17, 2013

Tweet Aridis Pharmaceuticals is buying Kenta Biotech’s anti-infection treatment products for an undisclosed amount. The acquisition includes six products to treat infections, such as skin infections or respiratory infections, caused by common pathogens. Aridis is also buying a technology that helps discover naturally occurring protective antibodies generated by the human immune system. Terms of the deal were not disclosed. Aridis, headquartered in San Jose, Calif., focuses on developing anti-infective drugs to treat lung infections and other infections. Zurich-based Kenta also develops medications to treat infections. Other recent pharmaceutical deals include Takeda Pharmaceutical Co. Ltd.’s purchase of Inviragen , Auxilium Pharmaceuticals Inc.’s (Nasdaq: AUXL) Actient Holdings LLC  and Opko Health Inc.’s (NYSE: OPK) acquisition of Prolor Biotech Inc. (NYSE: PBTH).   

Kenta Biotech Frequently Asked Questions (FAQ)

  • Who are Kenta Biotech's competitors?

    Competitors of Kenta Biotech include Biosceptre International, Raptor Pharmaceutical Corp., Viventia, Open Monoclonal Technology, Idenix Pharmaceuticals and 14 more.

Compare Kenta Biotech to Competitors

A
Arisyn Therapeutics

Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.

S
Spaltudaq

Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

A
Adriacell

Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

A
Abeome

Abeome is a biotechnology firm dedicated to leveraging its technology that aims to enhance the speed, efficiency and stability of developing and producing monoclonal antibodies.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

A
Aliva Biopharmaceuticals

Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.